This article is more than 5 years old. Information may no longer be current.

Rockwell Medical renames iron drug for dialysis patients Triferic

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The U.S. Food & Drug Administration has accepted the proposed trade name Triferic for Rockwell Medical's investigational iron-delivery drug, previously known as Soluble Ferric Pyrophosphate (SFP), which is intended for treating iron deficiency in chronic kidney disease patients receiving hemodialysis, Rockwell announced.

"We believe that upon FDA approval, Triferic will become the new standard of care in iron therapy," said Rob Chioini, chairman and CEO of Rockwell Medical.
Rockwell recently announced successful top-line results from its long-term Phase 3 CRUISE-1 and CRUISE-2 efficacy studies of Triferic. In both studies, Triferic met the primary endpoint, demonstrating a statistically significant mean change in hemoglobin from baseline to end-of-treatment.